Expression of the Androgen Receptor, pAkt, and pPTEN in Breast Cancer and Their Potential in Prognostication

Translational Oncology

Volumn 7, Issue 3, 2014, Pages 355-362

  Sultana, Aisha ^a   Idress, Romana ^a   Naqvi, Zulfiqar Ali ^a   Azam, Iqbal ^a   Khan, Shaista ^a   Siddiqui, Anwar Ali ^a   Lalani, El Nasir ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84905991828     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.04.004     Document Type: Article

References (55)

1. Bray, F., McCarron, P., Parkin, D.M., The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6 (2004), 229–239.
2. Kakarala, M., Rozek, L., Cote, M., Liyanage, S., Brenner, D.E., Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S. - a SEER analysis. BMC Cancer, 10, 2010, 191.
3. Bhurgri, Y., Kayani, N., Faridi, N., Pervez, S., Usman, A., Bhurgri, H., Malik, J., Bashir, I., Bhurgri, A., Hasan, S.H., et al. Patho-epidemiology of breast cancer in Karachi '1995-1997'. Asian Pac J Cancer Prev 8 (2007), 215–220.
4. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987), 177–182.
5. Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989), 707–712.
6. Faheem, M., Mahmood, H., Khurram, M., Qasim, U., Irfan, J., Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan. Ecancermedicalscience, 6, 2012, 283.
7. Sharif, M.A., Mamoon, N., Mushtaq, S., Khadim, M.T., Jamal, S., Steroid hormone receptor association with prognostic markers in breast carcinoma in Northern Pakistan. J Coll Physicians Surg Pak 20 (2010), 181–185.
8. Aziz, S.A., Pervez, S., Khan, S., Kayani, N., Azam, S.I., Rahbar, M.H., Significance of immunohistochemical c-ErbB-2 product localisation pattern for prognosis in human breast cancer. Pathol Oncol Res 7 (2001), 190–196.
9. Moatter, T., Aban, M., Iqbal, W., Azam, I., Pervaiz, A., Siddiqui, F., Murad, F., Pervez, S., Status of HER2 amplification, polysomy 17 and histopathological features of 425 Pakistani breast cancer patients. Asian Pac J Cancer Prev 12 (2011), 3069–3073.
10. Bryan, R.M., Mercer, R.J., Bennett, R.C., Rennie, G.C., Lie, T.H., Morgan, F.J., Androgen receptors in breast cancer. Cancer 54 (1984), 2436–2440.
11. Hu, R., Dawood, S., Holmes, M.D., Collins, L.C., Schnitt, S.J., Cole, K., Marotti, J.D., Hankinson, S.E., Colditz, G.A., Tamimi, R.M., Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 17 (2011), 1867–1874.
12. Qu, Q., Mao, Y., Fei, X.C., Shen, K.W., The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS One, 8, 2013, e82650.
13. Søreide, J.A., Lea, O.A., Varhaug, J.E., Skarstein, A., Kvinnsland, S., Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 18 (1992), 112–118.
14. Schippinger, W., Regitnig, P., Dandachi, N., Wernecke, K.D., Bauernhofer, T., Samonigg, H., Moinfar, F., Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch 449 (2006), 24–30.
15. Narita, D., Raica, M., Suciu, C., Cîmpean, A., Anghel, A., Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer. Folia Histochem Cytobiol 44 (2006), 165–172.
16. Riva, C., Dainese, E., Caprara, G., Rocca, P.C., Massarelli, G., Tot, T., Capella, C., Eusebi, V., Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows Arch 447 (2005), 695–700.
17. Mishra, A.K., Agrawal, U., Negi, S., Bansal, A., Mohil, R., Chintamani, C., Bhatnagar, A., Bhatnagar, D., Saxena, S., Expression of androgen receptor in breast cancer & its correlation with other steroid receptors & growth factors. Indian J Med Res 135 (2012), 843–852.
18. Agrawal, A.K., Jeleń, M., Grzebieniak, Z., Zukrowski, P., Rudnicki, J., Nienartowicz, E., Androgen receptors as a prognostic and predictive factor in breast cancer. Folia Histochem Cytobiol 46 (2008), 269–276.
19. Yu, Q., Niu, Y., Liu, N., Zhang, J.Z., Liu, T.J., Zhang, R.J., Wang, S.L., Ding, X.M., Xiao, X.Q., Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol 22 (2010), 1288–1294.
20. Pérez-Tenorio, G., Stål, O., Southeast Sweden Breast Cancer Group. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86 (2002), 540–545.
21. Song, G., Ouyang, G., Bao, S., The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9 (2005), 59–71.
22. Crowder, R.J., Ellis, M.J., Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway. Breast Cancer Res 7 (2005), 212–214.
23. Liang, K., Jin, W., Knuefermann, C., Schmidt, M., Mills, G.B., Ang, K.K., Milas, L., Fan, Z., Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2 (2003), 353–360.
24. Ghosh, A.K., Grigorieva, I., Steele, R., Hoover, R.G., Ray, R.B., PTEN transcriptionally modulates c-myc gene expression in human breast carcinoma cells and is involved in cell growth regulation. Gene 235 (1999), 85–91.
25. Paez, J., Sellers, W.R., PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 115 (2003), 145–167.
26. Nagata, Y., Lan, K.H., Zhou, X., Tan, M., Esteva, F.J., Sahin, A.A., Klos, K.S., Li, P., Monia, B.P., Nguyen, N.T., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 (2004), 117–127.
27. Wang, Y., Romigh, T., He, X., Tan, M.H., Orloff, M.S., Silverman, R.H., Heston, W.D., Eng, C., Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene 30 (2011), 4327–4338.
28. Wang, Y., He, X., Ngeow, J., Eng, C., GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. Hum Mol Genet 21 (2012), 569–576.
29. Schmitz, K.J., Otterbach, F., Callies, R., Levkau, B., Hölscher, M., Hoffmann, O., Grabellus, F., Kimmig, R., Schmid, K.W., Baba, H.A., Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol 17 (2004), 15–21.
30. Vestey, S.B., Sen, C., Calder, C.J., Perks, C.M., Pignatelli, M., Winters, Z.E., Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome. Eur J Cancer 41 (2005), 1017–1025.
31. Esteva, F.J., Guo, H., Zhang, S., Santa-Maria, C., Stone, S., Lanchbury, J.S., Sahin, A.A., Hortobagyi, G.N., Yu, D., PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177 (2010), 1647–1656.
32. Polak, J.M., Van Noorden, S., Introduction to Immunocytochemistry, Second edition, 1997, BIOS Scientific Publishers.
33. Park, S., Koo, J., Park, H.S., Kim, J.H., Choi, S.Y., Lee, J.H., Park, B.W., Lee, K.S., Expression of androgen receptors in primary breast cancer. Ann Oncol 21 (2010), 488–492.
34. Aleskandarany, M.A., Rakha, E.A., Ahmed, M.A., Powe, D.G., Ellis, I.O., Green, A.R., Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Res Treat 127 (2011), 407–416.
35. Allred, D.C., Harvey, J.M., Berardo, M., Clark, G.M., Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11 (1998), 155–168.
36. Niemeier, L.A., Dabbs, D.J., Beriwal, S., Striebel, J.M., Bhargava, R., Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 23 (2010), 205–212.
37. Depowski, P.L., Rosenthal, S.I., Ross, J.S., Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 14 (2001), 672–676.
38. Dunnwald, L.K., Rossing, M.A., Li, C.I., Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res, 9, 2007, R6.
39. Nadji, M., Gomez-Fernandez, C., Ganjei-Azar, P., Morales, A.R., Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 123 (2005), 21–27.
40. Langer, M., Kubista, E., Schemper, M., Spona, J., Androgen receptors, serum androgen levels and survival of breast cancer patients. Arch Gynecol Obstet 247 (1990), 203–209.
41. Søiland, H., Kørner, H., Skaland, I., Janssen, E.A., Gudlaugsson, E., Varhaug, J.E., Baak, J.P., Søreide, J.A., Prognostic relevance of androgen receptor detection in operable breast cancer. J Surg Oncol 98 (2008), 551–558.
42. Castellano, I., Allia, E., Accortanzo, V., Vandone, A.M., Chiusa, L., Arisio, R., Durando, A., Donadio, M., Bussolati, G., Coates, A.S., et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 124 (2010), 607–617.
43. Park, S., Koo, J.S., Kim, M.S., Park, H.S., Lee, J.S., Lee, J.S., Kim, S.I., Park, B.W., Lee, K.S., Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol 22 (2011), 1755–1762.
44. Peters, A.A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M.M., Harris, J.M., Jindal, S., Segara, D., Jia, L., Moore, N.L., et al. Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Cancer Res 69 (2009), 6131–6140.
45. Agoff, S.N., Swanson, P.E., Linden, H., Hawes, S.E., Lawton, T.J., Androgen receptor expression in estrogen receptor–negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 120 (2003), 725–731.
46. Cleator, S.J., Ahamed, E., Coombes, R.C., Palmieri, C., A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer 9:Suppl 1 (2009), S6–S17.
47. Bedard, P.L., Freedman, O.C., Howell, A., Clemons, M., Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?. Breast Cancer Res Treat 108 (2008), 307–317.
48. Ma, C.X., Sanchez, C.G., Ellis, M.J., Predicting endocrine therapy responsiveness in breast cancer. Oncology 23 (2009), 133–142.
49. Lundin, K.B., Henningson, M., Hietala, M., Ingvar, C., Rose, C., Jernström, H., Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients. Br J Cancer 105 (2011), 1676–1683.
50. Park, S., Park, H.S., Koo, J.S., Yang, W.I., Kim, S.I., Park, B.W., Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers. Breast Cancer Res Treat 133 (2012), 311–320.
51. Macedo, L.F., Guo, Z., Tilghman, S.L., Sabnis, G.J., Qiu, Y., Brodie, A., Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 66 (2006), 7775–7782.
52. Shi, W., Zhang, X., Pintilie, M., Ma, N., Miller, N., Banerjee, D., Tsao, M.S., Mak, T., Fyles, A., Liu, F.F., Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int J Cancer 104 (2003), 195–203.
53. Stambolic, V., Suzuki, A., de la Pompa, J.L., Brothers, G.M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J.M., Siderovski, D.P., Mak, T.W., Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95 (1998), 29–39.
54. Lin, H.K., Yeh, S., Kang, H.Y., Chang, C., Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci U S A 98 (2001), 7200–7205.
55. Lin, H.K., Wang, L., Hu, Y.C., Altuwaijri, S., Chang, C., Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 21 (2002), 4037–4048.